Credit Suisse Ag Affimed N.V. Transaction History

Credit Suisse Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$1.1 - $2.45 $887 - $1,977	-807 Reduced 99.26%	6 $0
Q3 2022 Nov 10, 2022	BUY	$1.96 - $3.32 $1,532 - $2,596	782 Added 2522.58%	813 $2,000
Q2 2022 Aug 12, 2022	BUY	$2.27 - $4.86 $70 - $150	31 New	31 $0
Q2 2021 Aug 16, 2021	SELL	$7.78 - $11.4 $99,786 - $146,216	-12,826 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$5.12 - $8.48 $38,067 - $63,048	-7,435 Reduced 36.7%	12,826 $101,000
Q4 2020 Feb 12, 2021	BUY	$3.16 - $7.03 $64,024 - $142,434	20,261 New	20,261 $117,000
Q4 2019 Feb 12, 2020	SELL	$2.25 - $3.07 $32,357 - $44,149	-14,381 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$2.67 - $3.65 $38,397 - $52,490	14,381 New	14,381 $42,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $154M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.